Hideaki Miyake
Overview
Explore the profile of Hideaki Miyake including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
518
Citations
3168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirata J, Hara T, Jimbo N, Ueki H, Okamura Y, Bando Y, et al.
Anticancer Res
. 2025 Mar;
45(3):1137-1147.
PMID: 40037891
Background/aim: This study aimed to investigate the genomic features of small cell neuroendocrine prostate cancer (SCPC) in Japanese patients, assess their relationships with platinum-based chemotherapy efficacy, and evaluate the potential...
2.
A R, Ueki H, Nishioka S, Yamazaki R, Maekawa M, Kitagawa K, et al.
Cancer Gene Ther
. 2025 Feb;
PMID: 40011711
Muscle-invasive bladder cancer (MIBC), a highly heterogeneous disease, shows genomic instability and a high mutation rate, making it difficult to treat. Recent studies revealed that cancer stem cells (CSCs) play...
3.
Hara T, Suzuki K, Watanabe H, Motoyama D, Otsuka A, Miyake H
Asian J Endosc Surg
. 2025 Feb;
18(1):e70041.
PMID: 40011025
Introduction: Inferior vena cava (IVC) tumor thrombus occurs in 4%-10% of renal cell carcinoma (RCC) cases. Robotic-assisted radical nephrectomy (RARN) with IVC tumor thrombectomy offers a minimally invasive alternative to...
4.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, Oki E, Karasaki T, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39920551
Although the 5-year relative survival rates for resectable solid tumors have improved over the past few years, the risk of postoperative recurrence necessitates effective monitoring strategies. Recent advancements in molecular...
5.
Hara T, Nishimoto H, Terakawa T, Okamura Y, Bando Y, Ueki H, et al.
Int J Clin Oncol
. 2025 Feb;
PMID: 39918769
Objectives: Prostate cancer patients receiving androgen deprivation therapy (ADT) have increased risks of decreased bone mineral density (BMD). However, there are no established guidelines for assessing BMD in patients with...
6.
Furukawa J, Kakei Y, Murakami S, Kita H, Ueki H, Hara T, et al.
BMC Cancer
. 2025 Feb;
25(1):195.
PMID: 39905323
Background: This is a multicenter, open-label, single-arm clinical trial to evaluate the safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer. Methods: The...
7.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, et al.
Jpn J Clin Oncol
. 2025 Feb;
PMID: 39893579
Objective: To validate multiple prognostic models in metastatic renal cell carcinoma patients who received second-line axitinib following first-line nivolumab plus ipilimumab therapy. Methods: Five prognostic models (ACL, albumin, C-reactive protein,...
8.
Possible mechanisms of spermatogenic dysfunction induced by viral infections: Insights from COVID-19
Okada K, Kin C, Yamashita Y, Kawamura S, Sato K, Chiba K, et al.
Reprod Med Biol
. 2025 Jan;
24(1):e12625.
PMID: 39845480
Background: As the COVID-19 pandemic nears resolution in 2024, the mechanisms by which SARS-CoV-2 and other viral infections induce spermatogenic dysfunction remain poorly understood. This review examines the mechanisms by...
9.
Sato K, Koyanagi-Aoi M, Uehara K, Yamashita Y, Shinohara M, Lee S, et al.
Stem Cell Reports
. 2025 Jan;
20(2):102392.
PMID: 39824187
Late-onset hypogonadism (LOH) syndrome is characterized by age-related testosterone deficiency and negatively affects the quality of life of older men. A promising therapeutic approach for LOH syndrome is transplantation of...
10.
Tashiro Y, Hyodo Y, Kitamura S, Fujimoto T, Endo T, Nishioka S, et al.
Clin Exp Nephrol
. 2025 Jan;
PMID: 39804516
Background: This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia...